Infant Bacterial Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Infant Bacterial Therapeutics has a total shareholder equity of SEK204.0M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK239.3M and SEK35.3M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 226.20m |
| Equity | SEK 204.03m |
| Total liabilities | SEK 35.28m |
| Total assets | SEK 239.30m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9IB's short term assets (SEK230.1M) exceed its short term liabilities (SEK35.3M).
Long Term Liabilities: 9IB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 9IB is debt free.
Reducing Debt: 9IB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9IB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9IB has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 18.1% each year.